Monthly Archives: January 2011

New Year Night Stalkers: What Will Keep the C-Suiters Awake in 2011

By William Looney | Published: January 5, 2011
New Year Night Stalkers Eight Strategic Issues that Should Keep “C Suiters” Reaching for the NoDoz in 2011 The consensus is that 2011 will be a bad year for big pharma.  It must confront a breaking wave of patent expirations, while fiscal retrenchment has created an innovation cycle in reverse as payers find new ways to curb [...]
Posted in Manufacturing, Marketing, R&D, Regulatory, Strategy, Technology, compliance | Tagged , , | 5 Comments

What Can Big Pharma Learn From Other Industries in Emerging Markets?

By William Looney | Published: January 5, 2011
Building a durable base for growth in emerging markets is top line in pharma’s strategy to compensate for slowing sales in the US and Europe.   Key to success is moving beyond the traditional reliance on serving the smallest, most affluent segment of the market to seed critical mass: expanding resources for health, broadening the customer [...]
Posted in Emerging Markets, IP, Market Access, Marketing, Strategy | Tagged , | 1 Comment

Mobile Health: Will Cellular Doom the Paper Chase?

By Jennifer Ringler | Published: January 4, 2011
Eric Boothe discusses the use of mobile technology among physicians, and the practical application of 2D Barcodes for sales and marketing purposes in the pharma industry. While print continues to be a standard for marketing initiatives in our industry, new opportunities for engagement with health care practitioners (HCP) and patients are becoming readily available. Recently, [...]
Posted in Guest Blog | Tagged , , | 2 Comments